Daniel Resnick, MS, MD (Madison, WI), Eeric Truumees, MD (Austin, TX), Zoher Ghogawala, MD (Boston, MA) and Jeffrey Wang, MD (Los Angeles, CA) discuss the trends in treatment of degenerative spondylolisthesis.

Disclosures:

Ghogawala, Zoher: Board of Directors: Cervical Spine Research Society (Nonfinancial, Research Committee Chair, Registry Director), GN2.0-Nidus (66%), Joint Spine Section - AANS-CNS (Nonfinancial, Chair).

Resnick, Daniel K.: Scientific Advisory Board: NIDUS (None).

Truumees, Eeric: Board of Directors: Seton Family of Doctors (No additional pay, part of base compensation); Other Office: AAOS Communications Cabinet (E); Research Support (Staff and/or materials): Dova Pharmaceuticals (A, Paid directly to institution/employer), Medtronic (C, Paid directly to institution/employer), Pfizer (E, Paid directly to institution/employer), Relievant (F, Paid directly to institution/employer), Stryker Spine (B, Paid directly to institution/employer), Vertex Pharma (D, Study cancelled, Outside 12-Month Requirement, Paid directly to institution/employer); Trips/Travel: AAOS (Travel Reimbursement).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+